Vlad Vitoc, MD, MBA
His experience includes managing and supporting over 20 early, launch, and mature stage compounds, amongst which targeted therapies and immune therapies, across more than 25 tumor types – amongst which colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, renal cell carcinoma. In his previous role at Barricade Therapeutics, he served as the Chief Business Officer and SVP Medical Affairs, leading the capitalization efforts and the pharmaceutical business development activities. At Puma Biotechnology, he served as VP Medical Affairs and built the Medical organization supporting the launch of NERLYNX (neratinib) in extended adjuvant breast cancer. Before Puma, Dr. Vitoc was the Executive Medical Director for pipeline products at Incyte Corporation, establishing the medical affairs support for compounds transitioning from preclinical to phase I and II clinical trials. Before that, he was Sr Medical Director at Astellas Pharma Inc., supporting the launch and development of XTANDI (enzalutamide), the life cycle management of TARCEVA (erlotinib), as well as pipeline compounds. Earlier in his career, he served in commercial strategic analysis and planning leadership roles centered on life cycle management, business development, and forecasting at Cephalon Oncology, Novartis Oncology, Bayer Oncology, and Pharmacia & Upjohn. He obtained his medical training at the University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj-Napoca, Romania, and his MBA at the University of South Carolina.
Angela Wang, CPA EMBA
She started her career with one of the Big 6 accounting firms and worked alongside China’s Ministry of Finance in developing China’s first set of accounting standards. Following her appointment in public accounting, she joined the pharma industry in financial and commercial leadership roles in increasing levels of responsibilities over the years. First as Country CFO in China for Novartis, Angela led the funding and financial responsibilities for 10 subsidiaries and set up the first corporate finance function. Subsequently, she become Group Controller in the Novartis head office in Switzerland, working alongside the Group CEO and CFO, responsible for the global Pharma division covering planning, analysis, and review of all major investments, divestments and mergers and acquisitions.
With growing investments in China, Angela returned to build and lead the China Pharma strategy and business development function. Aligned with the long-term plan, Angela led the team to identify, negotiate and implement in-license and out-license partnerships in the areas of dermatology, liver disease, and incontinence. Meanwhile, as China is a high prevalence country for hepatitis, she led a cross-functional team comprising local and global counterparts in clinical, regulatory, pricing, manufacturing and marketing towards expediting approval of the local hepatitis B treatment Sebivo. Subsequently, Angela was the Business Unit Head for Ophthalmology, responsible for sales and marketing where she turned around a historically underperforming business and led the team to exceed sales targets with double digit growth. With strong customer relations, the team also won support from key opinion leaders to initiate a fast-track approval request for Lucentis.
Following Novartis, Angela was CFO for Syngenta, supporting its China Agrichemical business responsible for planning, accounting, internal controls, pricing, and compliance. She was also the CFO for Sanofi China supporting over $1 billion in sales, covering Finance, Legal, Supply Chain and Site Management.
Beyond corporations, Angela also works closely with startups as an entrepreneurial advisor to support their early stage growth, business development and scale up. As a senior advisor to a global non-profit think tank, she has published with focus on innovation, research and development. Angela has worked in Europe, Asia and North America, and speaks Mandarin, German and French.
Angela is a Certified Public Accountant and holds an Executive Master of Business Administration from the International Institute for Management Development (IMD) in Lausanne, Switzerland, and a Bachelor of Science in Financial Accounting from Rutgers University in New Brunswick, New Jersey.
Mr. Relovsky was the founding and managing partner for Clarity Global Solutions LLC, a consulting firm specializing in commercial value development and operational support to biotech and pharmaceutical companies, with primary focus on early-mid stage asset development and product planning building commercial value. Additionally, CGS specializes in therapeutic area market development and engagement, Medical Affairs and Commercial Operations management, with particular focus on commercialization and launch preparation.
Mr. Relovsky began his career in Finance for Squibb-Novo, Inc. (now Novo Nordisk Pharmaceuticals, Inc.) and over the years has held various management positions, with increasing levels of responsibility, including leading operations functional areas, Product Planning and Marketing, addressing both company-wide and product level initiatives. Most recently, Mr. Relovsky has established and led the Commercial Operations and launch planning for ARS Pharmaceuticals, Inc. for an intranasal form of epinephrine (ARS-1). Prior to ARS, he led Medical Affairs Operations for Puma Biotechnology, Inc. through the launch of NERLYNX (neratinib), a tyrosine kinase inhibitor approved for the treatment of breast cancer. He has also held positions leading Commercial Operations for Somaxon Pharmaceuticals, Inc. which launched SILENOR (doxepin) for the treatment of insomnia; and Marketing for Cephalon, Inc. where he established the oncology franchise that included the product re-launch of TRISENOX (arsenic trioxide) in acute promyelocytic leukemia (APL) and launch of TREANDA (bendamustine) in two indications: chronic lymphocytic leukemia (CLL) and indolent non-hodgkin lymphoma (NHL). Other previous positions include product planning and marketing with Salmedix, Inc., Maxim Pharmaceuticals, Inc.; and commercial operations with Agouron Pharmaceutics, Inc. all based in San Diego, CA; and IMS Health (now IQVIA). Additionally, Mr. Relovsky held the role of Vice President, Development & Board Member for the American Melanoma Foundation.
Mr. Relovsky holds a Bachelor of Science, Business Administration and Finance from Drexel University in Philadelphia, PA.
Wayne Klohs, PH.D.
In five years at Astellas, Dr. Klohs helped build Oncology into a global business with several marketed products including Tarceva® and Xtandi® and helped build a robust oncology pipeline through in-licensing, the acquisition of OSI, and internal discovery. He was responsible for the successful filings of NDAs and MAAs for Xtandi (enzalutamide) and Tarceva (sNDA). Dr. Klohs’s previous experience includes acting head of Oncology Clinical Sciences at Takeda Global R&D and Executive Director of Oncology Drug Development at Pfizer, Inc. At Takeda, he led both early and late-stage Development Teams in Oncology, while at Pfizer, he was responsible for Development Teams from mid-Discovery through POC with additional experience in NDA filing of pentostatin/Nipent. Dr. Klohs led development teams at Pfizer and Parke-Davis to more than 14 successful IND filings and Phase 1 starts as well as leading late stage programs in biologics including monoclonal antibodies and an oncolytic adenovirus. Prior to his experience in drug development for oncology, he led discovery efforts at Warner-Lambert/Parke Davis Pharmaceutical Research in oncology for 16 years in a number of areas including antiangiogenic agents, multiple drug resistance, histone deacetylase inhibitors, and antifolates.